Lantern Pharma Achieves Clinical Validation in 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
Should l Buy LTRN?
"2025 was a defining year for Lantern Pharma as we achieved clinical validation across multiple programs while establishing the foundation for our next phase of growth," said Panna Sharma, CEO & President of Lantern Pharma. "The encouraging and developing LP-300 Phase 2 HARMONIC observations, combined with successful Phase 1a completion for LP-184 and FDA IND clearance for our pediatric CNS cancer program through Starlight Therapeutics, represent transformational milestones that validate and strengthen our AI-driven approach to precision oncology. Our full-year results reflect disciplined execution with a 19% reduction in total operating expenses year-over-year, even as we advanced multiple clinical programs through key inflection points and introduced a highly unique multi-agentic system aimed at conquering rare cancers. As we move into 2026, we are positioning to advance multiple high-value clinical programs, expand our RADR platform's commercial reach and revenue potential globally through our new AI Center of Excellence in India and strengthen our balance sheet."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LTRN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LTRN
Wall Street analysts forecast LTRN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.235
Low
25.00
Averages
25.00
High
25.00
Current: 1.235
Low
25.00
Averages
25.00
High
25.00
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lantern Pharma Reports Reduced Q4 Net Loss
- Reduced Quarterly Loss: Lantern Pharma reported a net loss of approximately $4.1 million for Q4 2025, a significant decrease from the $5.9 million loss in Q4 2024, indicating progress in cost management efforts.
- Cash Position: As of December 31, 2025, the company held approximately $10.1 million in cash and marketable securities, including about $4.4 million in cash, reflecting a decline in liquidity from $24 million in 2024, raising concerns about future financing needs.
- Operating Expense Decline: Total operating expenses for Q4 2025 were approximately $4.2 million, down from $5.9 million in Q4 2024, showcasing improvements in operational efficiency that could enhance future profitability.
- Financial Health Warning: Despite the reduced losses, cash reserves have decreased significantly from $24 million in 2024 to $10.1 million, indicating potential pressures on the company's ability to sustain operations, necessitating measures to bolster financial stability.
See More
Lantern Pharma Receives FDA IND Approval for STAR-001
- FDA IND Approval: Lantern Pharma and its subsidiary Starlight Therapeutics announced that the FDA has cleared the IND application for STAR-001, which is set to undergo a Phase 1 clinical trial in pediatric patients, marking a significant milestone in advancing pediatric neuro-oncology.
- Trial Design: The trial plans to enroll 18 to 42 pediatric patients aged 1 to 17 years, evaluating STAR-001 both as a single agent and in combination with spironolactone, covering various aggressive pediatric CNS malignancies, showcasing the company's strategic positioning in this field.
- Improved Financials: For the quarter ending September 30, 2025, Lantern Pharma reported a net loss of $4.2 million, an improvement from $4.5 million in the prior year, indicating positive progress in financial management, with cash expected to support operations into Q3 2026.
- Stock Price Volatility: Following the FDA approval announcement, Lantern Pharma's stock surged over 30% in pre-market trading to $1.45, reflecting market optimism regarding its clinical advancements, despite significant price fluctuations over the past year, with a low of $1.11.
See More
Lantern Pharma Q4 2025 Earnings Call Insights
- Significant Clinical Progress: Lantern Pharma achieved clinical validation across multiple programs in 2025, particularly with LP-300 in the Phase II HARMONIC trial, which demonstrated an 86% clinical benefit rate and a 43% objective response rate, indicating potential breakthroughs in cancer treatment.
- Urgent Funding Needs: Management emphasized the necessity to raise substantial additional funding in the near future to support clinical program advancements, with current cash expected to last until late July or mid-September 2026, highlighting operational pressures.
- AI Innovation Commercialization: The company launched the withZeta multi-agentic system aimed at conquering rare cancers and established an AI center of excellence in India, reflecting Lantern Pharma's strategic focus on AI-driven clinical pipelines and commercialization.
- Improved Financial Performance: In Q4 2025, R&D expenses were $2.7 million, significantly down from $4.3 million in the prior year, with a net loss of $4.1 million, demonstrating the company's efforts in cost control and gradual improvement in financial health.
See More
PMGC Holdings Unit Amends Clinical Trial Agreement
- Clinical Trial Agreement Amendment: PMGC Holdings' subsidiary NorthStrive Biosciences amended its deal with MOA Life Plus to conduct human trials for EL-22 and EL-32, targeting muscle and lean mass preservation, which is expected to enhance the company's competitive edge in the biopharmaceutical sector.
- Stock Price Surge: PMGC Holdings' shares soared over 66% in Monday's pre-market trading, despite a 95% year-to-date decline, indicating a positive market reaction to the new clinical trials that may attract investor interest.
- Iterum Therapeutics Winding-Up Petition: Iterum Therapeutics filed a winding-up petition in Ireland, set for hearing on April 13, 2026; although its stock rose 110% in pre-market trading, it remains down 90% year-to-date, reflecting market concerns about its future prospects.
- FDA Approval for New Drug Application: Lantern Pharma's STAR-001 received FDA clearance for clinical trials targeting relapsed or refractory CNS cancers, with shares gaining over 17% in pre-market trading, despite a 63% year-to-date decline, indicating market anticipation for its new therapy.
See More
Leading Pre-Market Gainers Today — ELAB, ITRM, LTRN Among Stocks Rising Ahead of Market Open
PMGC Holdings Update: PMGC Holdings announced an amended deal with MOA Life Plus to conduct human trials for EL-22 and EL-32, focusing on muscle and lean mass preservation.
Iterum Therapeutics Developments: Iterum Therapeutics filed a winding-up petition in Ireland, set for a hearing on April 13, 2026, while also announcing a significant increase in its stock value.
Lantheus Pharma Progress: Lantheus Pharma received FDA clearance for its new drug application for STAR-001, aimed at treating relapsed or refractory CNS malignancies, and saw a notable rise in its stock.
Market Sentiment: U.S. equities showed positive movement amid ongoing tensions in the Middle East, with retail sentiment regarding the S&P 500 ETF categorized as "extremely bearish."
See More
Lantern Pharma CEO Panna Sharma Remains in Position, Addresses False Claims
- Executive Stability: Lantern Pharma emphasizes that Panna Sharma remains as President and CEO, refuting false claims of his resignation, thereby ensuring investor confidence in the company's leadership.
- Clinical Pipeline Progress: Under Sharma's leadership, Lantern is advancing its clinical pipeline, including the recently cleared IND for STAR-001 targeting pediatric CNS cancer, demonstrating the company's proactive stance in oncology drug development.
- Legal Action Plan: Lantern is investigating the origin of the false article and considering legal remedies to protect the company and its shareholders from misleading information, showcasing its commitment to market integrity.
- Financial Performance Release: Lantern will host a webcast on March 30, 2026, to discuss Q4 and fiscal year 2025 operating and financial results, further enhancing transparency and providing investors with the latest updates.
See More
Lantern Pharma Reports Reduced Q4 Net Loss
- Reduced Quarterly Loss: Lantern Pharma reported a net loss of approximately $4.1 million for Q4 2025, a significant decrease from the $5.9 million loss in Q4 2024, indicating progress in cost management efforts.
- Cash Position: As of December 31, 2025, the company held approximately $10.1 million in cash and marketable securities, including about $4.4 million in cash, reflecting a decline in liquidity from $24 million in 2024, raising concerns about future financing needs.
- Operating Expense Decline: Total operating expenses for Q4 2025 were approximately $4.2 million, down from $5.9 million in Q4 2024, showcasing improvements in operational efficiency that could enhance future profitability.
- Financial Health Warning: Despite the reduced losses, cash reserves have decreased significantly from $24 million in 2024 to $10.1 million, indicating potential pressures on the company's ability to sustain operations, necessitating measures to bolster financial stability.
See More
Lantern Pharma Receives FDA IND Approval for STAR-001
- FDA IND Approval: Lantern Pharma and its subsidiary Starlight Therapeutics announced that the FDA has cleared the IND application for STAR-001, which is set to undergo a Phase 1 clinical trial in pediatric patients, marking a significant milestone in advancing pediatric neuro-oncology.
- Trial Design: The trial plans to enroll 18 to 42 pediatric patients aged 1 to 17 years, evaluating STAR-001 both as a single agent and in combination with spironolactone, covering various aggressive pediatric CNS malignancies, showcasing the company's strategic positioning in this field.
- Improved Financials: For the quarter ending September 30, 2025, Lantern Pharma reported a net loss of $4.2 million, an improvement from $4.5 million in the prior year, indicating positive progress in financial management, with cash expected to support operations into Q3 2026.
- Stock Price Volatility: Following the FDA approval announcement, Lantern Pharma's stock surged over 30% in pre-market trading to $1.45, reflecting market optimism regarding its clinical advancements, despite significant price fluctuations over the past year, with a low of $1.11.
See More
Lantern Pharma Q4 2025 Earnings Call Insights
- Significant Clinical Progress: Lantern Pharma achieved clinical validation across multiple programs in 2025, particularly with LP-300 in the Phase II HARMONIC trial, which demonstrated an 86% clinical benefit rate and a 43% objective response rate, indicating potential breakthroughs in cancer treatment.
- Urgent Funding Needs: Management emphasized the necessity to raise substantial additional funding in the near future to support clinical program advancements, with current cash expected to last until late July or mid-September 2026, highlighting operational pressures.
- AI Innovation Commercialization: The company launched the withZeta multi-agentic system aimed at conquering rare cancers and established an AI center of excellence in India, reflecting Lantern Pharma's strategic focus on AI-driven clinical pipelines and commercialization.
- Improved Financial Performance: In Q4 2025, R&D expenses were $2.7 million, significantly down from $4.3 million in the prior year, with a net loss of $4.1 million, demonstrating the company's efforts in cost control and gradual improvement in financial health.
See More
PMGC Holdings Unit Amends Clinical Trial Agreement
- Clinical Trial Agreement Amendment: PMGC Holdings' subsidiary NorthStrive Biosciences amended its deal with MOA Life Plus to conduct human trials for EL-22 and EL-32, targeting muscle and lean mass preservation, which is expected to enhance the company's competitive edge in the biopharmaceutical sector.
- Stock Price Surge: PMGC Holdings' shares soared over 66% in Monday's pre-market trading, despite a 95% year-to-date decline, indicating a positive market reaction to the new clinical trials that may attract investor interest.
- Iterum Therapeutics Winding-Up Petition: Iterum Therapeutics filed a winding-up petition in Ireland, set for hearing on April 13, 2026; although its stock rose 110% in pre-market trading, it remains down 90% year-to-date, reflecting market concerns about its future prospects.
- FDA Approval for New Drug Application: Lantern Pharma's STAR-001 received FDA clearance for clinical trials targeting relapsed or refractory CNS cancers, with shares gaining over 17% in pre-market trading, despite a 63% year-to-date decline, indicating market anticipation for its new therapy.
See More
Leading Pre-Market Gainers Today — ELAB, ITRM, LTRN Among Stocks Rising Ahead of Market Open
PMGC Holdings Update: PMGC Holdings announced an amended deal with MOA Life Plus to conduct human trials for EL-22 and EL-32, focusing on muscle and lean mass preservation.
Iterum Therapeutics Developments: Iterum Therapeutics filed a winding-up petition in Ireland, set for a hearing on April 13, 2026, while also announcing a significant increase in its stock value.
Lantheus Pharma Progress: Lantheus Pharma received FDA clearance for its new drug application for STAR-001, aimed at treating relapsed or refractory CNS malignancies, and saw a notable rise in its stock.
Market Sentiment: U.S. equities showed positive movement amid ongoing tensions in the Middle East, with retail sentiment regarding the S&P 500 ETF categorized as "extremely bearish."
See More
Lantern Pharma CEO Panna Sharma Remains in Position, Addresses False Claims
- Executive Stability: Lantern Pharma emphasizes that Panna Sharma remains as President and CEO, refuting false claims of his resignation, thereby ensuring investor confidence in the company's leadership.
- Clinical Pipeline Progress: Under Sharma's leadership, Lantern is advancing its clinical pipeline, including the recently cleared IND for STAR-001 targeting pediatric CNS cancer, demonstrating the company's proactive stance in oncology drug development.
- Legal Action Plan: Lantern is investigating the origin of the false article and considering legal remedies to protect the company and its shareholders from misleading information, showcasing its commitment to market integrity.
- Financial Performance Release: Lantern will host a webcast on March 30, 2026, to discuss Q4 and fiscal year 2025 operating and financial results, further enhancing transparency and providing investors with the latest updates.
See More
